Growth-inhibitory effects of vitamin D analogues and retinoids on human pancreatic cancer cells.

por Zugmaier, G., Jäger, R., Grage, B., Gottardis, M. M., Havemann, K., Knabbe, C.
Publicado 1996

Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients

por Jäger, R, List, B, Knabbe, C, Souttou, B, Raulais, D, Zeiler, T, Wellstein, A, Aigner, A, Neubauer, A, Zugmaier, G
Publicado 2002

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment

por Mejstríková, E., Hrusak, O., Borowitz, M. J., Whitlock, J. A., Brethon, B., Trippett, T. M., Zugmaier, G., Gore, L., von Stackelberg, A., Locatelli, F.
Publicado 2017

A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

por Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Publicado 2007

Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia

por Zugmaier, G, Topp, M S, Alekar, S, Viardot, A, Horst, H-A, Neumann, S, Stelljes, M, Bargou, R C, Goebeler, M, Wessiepe, D, Degenhard, E, Gökbuget, N, Klinger, M
Publicado 2014

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia

por Topp, M S, Stelljes, M, Zugmaier, G, Barnette, P, Heffner, L T, Trippett, T, Duell, J, Bargou, R C, Holland, C, Benjamin, J E, Klinger, M, Litzow, M R
Publicado 2018